05:29 , Feb 8, 2019 |  BC Week In Review  |  Clinical News

Samumed unveils MOA for Wnt inhibitor OA therapy

Samumed LLC (San Diego, Calif.) reported preclinical data showing that its small molecule Wnt pathway inhibitor osteoarthritis therapy, SM04690, functions through CLK-2 and DYRK1A inhibition. Data were presented at the Orthopaedic Research Society meeting in...
08:00 , Mar 3, 2016 |  BC Innovations  |  Targets & Mechanisms

Rescue mission

A pair of preclinical studies published last month on the autism target SHANK3 provide what might be the most meaningful progress for patients since the gene was linked with the disease over a decade ago....
08:00 , Feb 25, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Protein kinase B (AKT; AKT1; PKB; PKBA); CDC-like kinase 2 (CLK-2); SH3 and multiple ankyrin repeat domains 3 (SHANK3; PROSAP2; SPANK-2)

Neurology INDICATION: Autism Patient sample and rodent studies suggest inhibiting CLK-2 or activating AKT could help treat Phelan-McDermid syndrome (PMDS) or autism in patients harboring SHANK3 mutations. Levels of T308-phosphorylated AKT were lower in induced...
08:00 , Jan 28, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Indication

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes CDC-like kinase 2 (CLK2) Studies in cell culture and in mice suggest that increasing CLK2 activity could help treat diabetes. In cultured murine...
08:00 , Nov 25, 2002 |  BC Week In Review  |  Company News

Chronogen, McGill University deal

Chronogen exclusively licensed from the university proteins CLK-1 , CLK-2, and ISP-1, in addition to a series of targets for age-dependent diseases like cardiovascular disorders and cancer. The company said the proteins are associated in...